What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.53) per share for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2025 earnings at ($0.62) EPS and Q4 2025 earnings at ($0.83) EPS.

LENZ has been the topic of a number of other reports. TD Cowen began coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price objective on the stock. Citigroup increased their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LENZ Therapeutics presently has an average rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Trading Up 0.6 %

Shares of NASDAQ LENZ opened at $26.66 on Monday. The stock has a market capitalization of $733.18 million, a price-to-earnings ratio of -5.59 and a beta of 0.58. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93. The firm’s 50-day moving average price is $24.22 and its 200-day moving average price is $27.10.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Investors Weigh In On LENZ Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in LENZ Therapeutics by 5.3% in the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock valued at $34,022,000 after acquiring an additional 59,630 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of LENZ Therapeutics by 83.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock worth $23,760,000 after purchasing an additional 374,326 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in shares of LENZ Therapeutics in the fourth quarter worth about $22,243,000. State Street Corp increased its stake in LENZ Therapeutics by 18.7% in the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock worth $6,865,000 after buying an additional 45,600 shares during the period. Finally, Alyeska Investment Group L.P. lifted its holdings in LENZ Therapeutics by 16.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock valued at $4,103,000 after buying an additional 20,000 shares in the last quarter. 54.32% of the stock is owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.